Table of Contents

Appendix Figure S1.
Confocal microscopical analysis and quantitative analysis for colocalization of *M.tb* (GFP) with Lamp1 in Lamp1-mCherry-expressing BMMs pretreated with EVs in the presence of IFN-γ.
Page 2

Appendix Figure S2.
Confocal microscopical analysis and quantitative analysis for colocalization of *M.tb* (GFP) with Lamp1 in wild-type BMMs pretreated with EVs plus liposomal RNA from WT *M.tb* cells in the presence of IFN-γ.
Page 3

Appendix Figure S3.
Immunofluorescence microscopy analysis for *M.tb* colocalization with Ub and LC3 in BMMs pretreated with EVs in the presence of IFN-γ.
Page 4

Appendix Figure S4.
Immunofluorescence microscopy analysis for *M.tb* colocalization with Ub and LC3 in *M.tb*-infected BMMs treated with EVs in the presence of IFN-γ.
Page 5



Appendix Figure S1. Confocal microscopical analysis (A) and quantitative analysis (B) for colocalization of *M.tb* (GFP) with Lamp1 in Lamp1-mCherry-expressing BMMs pretreated with EVs in the presence of IFN-γ. Data shown in **(B)** are the mean ± SD of triple independent infections and all data shown are representative of at least three independent experiments. Scale bar, 5 μM. n.s., not significant; ** $p < 0.01$ by two-tailed Student's t-test.



Appendix Figure S2. Confocal microscopical analysis (A) and quantitative analysis (B) for colocalization of *M.tb* (GFP) with Lamp1 in wild-type BMMs pretreated with EVs plus liposomal RNA from WT *M.tb* cells in the presence of IFN-γ. Data shown in **(B)** are the mean ± SD of triple independent infections and all data shown are representative of at least three independent experiments. Scale bar, 5 μM. Mock, untreated. n.s., not significant by two-tailed Student's t-test.



Appendix Figure S3. Immunofluorescence microscopy analysis for *M.tb* colocalization with Ub and LC3 in BMMs pretreated with EVs in the presence of IFN-γ. (A) Representative photos from immunofluorescence microscopy analysis for *M.tb* colocalization with Ub BMMs. Cells were pretreated with EVs from *M.tb*-infected (EVs_*M.tb*) or uninfected (EVs_Control) BMMs in the presence of IFN-γ for 5 hr and then infected with GFP-expressing *M.tb* for 24 hr. Mock, no EVs treatment. **(B)** Similar to (A), but *M.tb* colocalization with LC3. **(C)** Western Blot to determine siRNA knockdown efficiency in BMMs. BMMs were treated with control siRNA or mouse TBK1-specific siRNA before EVs and IFN-γ treatment. . Scale bar, 5 μM. n.s., not significant; ** $p < 0.01$ by Student's t-test (two tailed).



Appendix Figure S4. Immunofluorescence microscopy analysis for *M.tb* colocalization with Ub and LC3 in *M.tb*-infected BMMs treated with EVs in the presence of IFN-γ. (A) Representative photos from immunofluorescence microscopy analysis for *M.tb* colocalization with Ub BMMs. Cells were infected with GFP-expressing *M.tb* for 24 hr and then treated with EVs from *M.tb*-infected (EVs_*M.tb*) or uninfected (EVs_Control) BMMs for 24 hr. Mock, no EVs treatment. **(B)** Similar to (A), but *M.tb* colocalization with LC3. BMMs were pre-treated with control siRNA or mouse TBK1-specific siRNA before *M.tb* infection. . Scale bar, 5 μM. n.s., not significant; ** $p < 0.01$ by Student's t-test (two tailed).